PARTNER NEWS:Fri, Apr 12, 11:55 AM, Zacks
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Fri, Feb 23, 8:55 AM, Zacks
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High? The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Featured MNV Articles: ZYME Crosses Below Key Moving Average Level
Wednesday, April 17, 4:49 PM ET, by Market News Video Staff
In trading on Wednesday, shares of Zymeworks Inc (ZYME) crossed below their 200 day moving ...
WVE Crosses Below Key Moving Average Level
Wednesday, April 17, 4:49 PM ET, by Market News Video Staff
In trading on Wednesday, shares of Wave Life Sciences Ltd (WVE) crossed below their 200 ...
Notable Two Hundred Day Moving Average Cross - SUPN
Wednesday, April 17, 4:45 PM ET, by Market News Video Staff
In trading on Wednesday, shares of Supernus Pharmaceuticals Inc (SUPN) crossed below their 200 day ...
Paychex Breaks Below 200-Day Moving Average - Notable for PAYX
Wednesday, April 17, 4:43 PM ET, by Market News Video Staff
In trading on Wednesday, shares of Paychex Inc (PAYX) crossed below their 200 day moving ...
Relative Strength Alert For Apellis Pharmaceuticals
Wednesday, April 17, 4:42 PM ET, by Market News Video Staff
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...
|
|
By Dividend Channel Staff, Wednesday, December 31, 7:00 PM ET
|